Gold R, Overmeyer A, Knie B, Fleming P C, Levison H
Pediatr Infect Dis. 1985 Mar-Apr;4(2):172-7. doi: 10.1097/00006454-198503000-00012.
A randomized controlled trial was undertaken to compare ceftazidime vs. the combination of ticarcillin and tobramycin in the treatment of acute respiratory exacerbations of mild to moderate severity in patients with cystic fibrosis. The two antibiotic regimens were equally effective in terms of clinical improvement: 16 of 17 in the ceftazidime group and 11 of 13 in the ticarcillin/tobramycin group were judged to be improved by the patients and attending physicians and were observed to show improvement in symptom scores, vital signs, body weight and pulmonary function. Ceftazidime was more effective bacteriologically in reducing colony counts of Pseudomonas aeruginosa in the sputum. Neither regimen affected Pseudomonas cepacia. Resistance to multiple antibiotics developed in six of 12 isolates of nonmucoid P. aeruginosa in patients receiving ticarcillin/tobramycin, which was significantly more than occurred in the ceftazidime group. There was no correlation between clinical and bacteriologic outcomes in either treatment group. No clinically important adverse effects were observed.
进行了一项随机对照试验，比较头孢他啶与替卡西林和妥布霉素联合用药治疗囊性纤维化患者轻至中度急性呼吸道加重的效果。就临床改善而言，两种抗生素治疗方案同样有效：头孢他啶组17例中有16例、替卡西林/妥布霉素组13例中有11例被患者和主治医生判定为病情改善，且观察到症状评分、生命体征、体重和肺功能均有改善。头孢他啶在细菌学上更有效地减少了痰液中铜绿假单胞菌的菌落计数。两种治疗方案对洋葱伯克霍尔德菌均无影响。接受替卡西林/妥布霉素治疗的患者中，12株非黏液型铜绿假单胞菌分离株中有6株出现了对多种抗生素的耐药性，这一情况显著多于头孢他啶组。两个治疗组的临床和细菌学结果之间均无相关性。未观察到具有临床意义的不良反应。
